Compare Crocs, Inc. (CROX) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crocs, Inc. vs Medpace Holdings Inc — how do they compare? Crocs, Inc. trades at $116.68 (market cap $5.60B), while Medpace Holdings Inc trades at $602 (market cap $16.82B). The key difference: Medpace Holdings Inc is far larger — about 3× Crocs, Inc.'s market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Crocs, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crocs, Inc. for 96 Days and Medpace Holdings Inc for 14 Days on average.
| CROX | MEDP | |
|---|---|---|
Market Cap | $5.60B | $16.82B |
Volume | 1,026,773 | 223,093 |
Sector | Consumer Cyclical | Health |
52-Week High | $141.19 | $630.19 |
52-Week Low | $73.39 | $393.42 |
Typical Hold Time | 96 Days | 14 Days |
Enterprise Value | $7.12B | $16.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CROX trades at $115.20, down 4.18% amid bearish technical signals, though valuation metrics appear attractive with a P/E of 10.23 and P/S of 1.46. Recent earnings beats and a 51% analyst buy rating support fundamental strength, but 2025 net income turned negative due to tax impacts. The stock faces resistance near $116-119 with support at $114.
Outlook remains mixed: strong brand positioning and earnings momentum contrast with technical weakness and recent profitability challenges. The consensus price target of $136.78 suggests 19% upside, but investors should weigh competitive pressures and consumer spending volatility against valuation appeal.
MEDP trades at $604.25, up 0.22% with neutral technical signals and strong fundamental performance. The stock shows robust profitability with 17.67% net income margin and consistent earnings beats in recent quarters. Recent news highlights institutional activity including CEO stock sales and upcoming Q3 2026 earnings report on October 21, 2026. Technical indicators show mixed signals with RSI neutral and ADX bullish, while support sits at $589 and resistance at $629.
MEDP presents a mixed outlook with strong fundamentals offset by high valuations and insider selling. The 21% buy rating from analysts suggests cautious optimism, with $620.44 price target offering 2.7% upside. Key risks include elevated P/E ratio of 35.5 and recent CEO stock sales totaling over $44 million in September 2026. Positive cash flow projection for 2026 supports growth potential despite current net outflow.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crocs, Inc.
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable geographic segments of the company include Americas, Asia pacific, and EMEA.
Read more on CROX →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
